


**eFigure 1. Application of MOSAIC trial eligibility criteria within the US Oncology Target Population.** Study inclusion diagram for the FOLFOX-treated target population. Individuals with missing values were considered as eligible for all inclusion criteria except for ECOG performance status (due to its inclusion in the sampling model).



**eFigure 2. Substage- and body mass index-stratified visualization of the distribution of inverse odds of sampling weights applied to the MOSAIC trial population for transport to the US Oncology target population.** A horizontal line at 10 denotes a threshold commonly used to identify potentially influential observations; the vertical line denotes the point in the distribution at which the weights exceed 10. Panel A shows the results for the cancer substage-stratified results and Panel B shows the body mass index-stratified results.